ANKRD26-Related Thrombocytopenia
文献摘要
Clinical characteristics ANKRD26-related thrombocytopenia (ANKRD26-RT) is characterized by lifelong mild-to-moderate thrombocytopenia with normal platelet size and no syndromic associations. Most individuals have normal hemostasis or a mild bleeding phenotype and do not develop severe spontaneous bleeding. Some individuals may have concomitant erythrocytosis and/or leukocytosis. The risk for myeloid malignancies (including myelodysplastic syndrome, acute myelogenous leukemia, and chronic myelogenous leukemia) is increased in individuals with ANKRD26 pathogenic variants. Diagnosis/testing The diagnosis of ANKRD26-RT is established in a proband by the presence of lifelong thrombocytopenia and a heterozygous pathogenic variant in ANKRD26 identified by molecular genetic testing. Management Treatment of manifestations: Hemostatic agents (e.g., antifibrinolytics, desmopressin) for bleeding or major surgical procedures; platelet transfusions are reserved for severe bleeding or procedures with high bleeding risk. Treatment of myeloid neoplasm per oncologist with careful consideration of stem cell transplant eligibility and pre-transplant therapies at an institution with experience in the management of individuals with germline predisposition syndromes. Surveillance: Surveillance for early detection of myeloid neoplasms should include annual evaluation by a hematologist with complete blood count including peripheral smear review, and if other cytopenias or abnormalities in mean corpuscular volume, cell morphology, or leukocyte differential are present, then additional bone marrow aspirate and biopsy with cytogenetic analysis and somatic myeloid next-generation sequencing testing. Agents/circumstances to avoid: Avoiding non-selective nonsteroidal anti-inflammatories and aspirin for pain management is recommended in all individuals with thrombocytopenia and/or increased bleeding risk; if a myeloid neoplasm that requires allogeneic stem cell transplantation develops and a related donor is being considered, a donor who does not have the ANKRD26 pathogenic variant present in the family should be used. Evaluation of relatives at risk: Offer molecular genetic testing for the familial ANKRD26 pathogenic variant to all older and younger at-risk relatives to identify as early as possible those who would benefit from prompt initiation of clinical surveillance for myeloid malignancy and targeted management of thrombocytopenia. Pregnancy management: Platelet counts and bleeding complications should be monitored during pregnancy; platelet counts under 70,000/uL can limit the ability to receive epidural analgesia or neuraxial anesthesia. Strategies to increase platelet count (transfusion) or use of thrombopoietin agonists can be considered on an individual basis in consultation with the anesthesiologist, hematologist, and maternal-fetal medicine specialist. Genetic counseling ANKRD26-RT is inherited in an autosomal dominant manner. To date, the great majority of individuals diagnosed with ANKRD26-RT have the disorder as the result of an ANKRD26 pathogenic variant inherited from a parent either known to be heterozygous based on molecular genetic testing or presumed to be heterozygous based on pedigree analysis or reported history of thrombocytopenia. (Note: Because the degree of thrombocytopenia varies within families and transient increase in platelet counts during inflammatory events may occur, molecular genetic testing is more accurate than assessment of thrombocytopenia for diagnosis of affected family members. Similarly, molecular genetic testing is beneficial to distinguish ANKRD26-RT from thrombocytopenia resulting from acquired causes, especially when prior platelet counts are not known.) Each child of an individual with ANKRD26-RT has a 50% chance of inheriting the ANKRD26 pathogenic variant. Once the ANKRD26 pathogenic variant has been identified in an affected family member, predictive testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.